EA200800290A1 - FORMULATION OF BENZIMIDAZOLE - Google Patents

FORMULATION OF BENZIMIDAZOLE

Info

Publication number
EA200800290A1
EA200800290A1 EA200800290A EA200800290A EA200800290A1 EA 200800290 A1 EA200800290 A1 EA 200800290A1 EA 200800290 A EA200800290 A EA 200800290A EA 200800290 A EA200800290 A EA 200800290A EA 200800290 A1 EA200800290 A1 EA 200800290A1
Authority
EA
Eurasian Patent Office
Prior art keywords
benzimidazole
dry
pharmaceutical formulation
formulation
production
Prior art date
Application number
EA200800290A
Other languages
Russian (ru)
Other versions
EA015535B1 (en
Inventor
Поул Бертелсен
Педер Мор Олсен
Original Assignee
Никомед Данмарк Апс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Никомед Данмарк Апс filed Critical Никомед Данмарк Апс
Publication of EA200800290A1 publication Critical patent/EA200800290A1/en
Publication of EA015535B1 publication Critical patent/EA015535B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Abstract

Описан способ сухого производства для получения фармацевтической формуляции бензимидазола и щелочного вещества. Таблетка прессована непосредственно из сухого порошка или сухих твердых частиц, избегая любой жидкости или вспомогательного вещества, которые обычно используются как связывающее для мокрой грануляции. Способ производства имеет преимущество из-за простоты и экономичности. В то же время дорогостоящий этап сушки является излишним. Полученная фармацевтическая формуляция имеет хорошую устойчивость и хороший профиль растворения.Describes the method of dry production for the pharmaceutical formulation benzimidazole and alkaline substances. The tablet is pressed directly from dry powder or dry solids, avoiding any liquid or adjuvant that is commonly used as a binder for wet granulation. The production method has an advantage due to its simplicity and economy. At the same time, an expensive drying step is unnecessary. The resulting pharmaceutical formulation has good stability and a good dissolution profile.

EA200800290A 2005-07-11 2006-07-11 Benzimidazole formulation EA015535B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200501019 2005-07-11
US72785505P 2005-10-19 2005-10-19
PCT/DK2006/000409 WO2006105798A2 (en) 2005-07-11 2006-07-11 Benzimidazole formulation

Publications (2)

Publication Number Publication Date
EA200800290A1 true EA200800290A1 (en) 2008-08-29
EA015535B1 EA015535B1 (en) 2011-08-30

Family

ID=37492042

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800290A EA015535B1 (en) 2005-07-11 2006-07-11 Benzimidazole formulation

Country Status (5)

Country Link
EP (1) EP1901719A2 (en)
AU (1) AU2006230974C1 (en)
CA (1) CA2614526A1 (en)
EA (1) EA015535B1 (en)
WO (1) WO2006105798A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5228359B2 (en) * 2007-04-12 2013-07-03 ニプロ株式会社 Active ingredient particles, process for producing the same and orally disintegrating tablets
KR20100129761A (en) 2008-03-11 2010-12-09 다케다 야쿠힌 고교 가부시키가이샤 Orally-disintegrating solid preparation
TR201000948A1 (en) * 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazole formulations.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN103479593B (en) * 2013-05-10 2014-10-08 青岛双鲸药业有限公司 Preparation method for omeprazole enteric coated tablet
CN103386133A (en) * 2013-07-09 2013-11-13 重庆莱美药业股份有限公司 Oral instant preparation of proton pump inhibitor and preparation method thereof
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
CA2976325C (en) 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN104825414B (en) * 2015-05-07 2018-11-16 山东新时代药业有限公司 A kind of stable S-pantoprazole sodium enteric tablet
KR20180018695A (en) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 Anticancer drug
CN113318079B (en) * 2021-05-13 2024-01-09 江西博莱大药厂有限公司 Method for improving dissolution rate of triclabendazole particles and dissolution rate detection method thereof
CN115645373B (en) * 2022-12-24 2024-01-30 山东理工职业学院 Preparation method of omeprazole sodium tablet

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
JP2001524131A (en) * 1997-05-09 2001-11-27 セイジ、ファーマスーティカルズ、インク Stable oral pharmaceutical dosage form
CN1141097C (en) * 1998-04-20 2004-03-10 卫材株式会社 Stabilized compositions containing benzimidzole-type compounds
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
AR036354A1 (en) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd SOLID PREPARATION
WO2004075881A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
EP2112920B1 (en) * 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
JP2007524646A (en) * 2003-07-17 2007-08-30 ドクター レディズ ラボラトリーズ， インコーポレイテッド Pharmaceutical composition having a swellable coating

Also Published As

Publication number Publication date
AU2006230974A1 (en) 2006-10-12
EP1901719A2 (en) 2008-03-26
WO2006105798A2 (en) 2006-10-12
AU2006230974C1 (en) 2012-02-02
AU2006230974B2 (en) 2011-09-29
EA015535B1 (en) 2011-08-30
CA2614526A1 (en) 2006-10-12
WO2006105798A3 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
EA200800290A1 (en) FORMULATION OF BENZIMIDAZOLE
RS52903B (en) Benzofuranyl derivatives used as glucokinase inhibitors
RS54587B1 (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
IS8920A (en) 3- (Phenyl or quinolyl) thio-1H-idanol-1-acetic acid derivative modulates the activity of CRTh2 antagonists.
MX2012010428A (en) Fine particulate flux.
WO2007090881A3 (en) Modified release formulation
RS51616B (en) Heteroaryl urea derivatives useful for inhibiting ghk1
IL189375A (en) 1-heterocyclylsulfonyl-3-aminomethyl, 5-(hetero)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
RS52607B (en) Solid pharmaceutical composition comprising valsartan
ATE496916T1 (en) QUINICLIDINE DERIVATIVES OF (HETERO)ARYLCYCLOHEPTANCARBOXIC ACIDS AS ANTAGONISTS ON THE MUSCARIN RECEPTOR
NO20074544L (en) Inhibition of HER2 release by matrix metalloprotease antagonists
NO20052601D0 (en) Use of special polysaccharides as additives to mineral materials.
EA200901365A1 (en) STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING PREGABALIN
DK1809253T3 (en) Stabilized freeze-dried formulation for cephalosporin derivatives
DK1989156T3 (en) PROCEDURE FOR DRYING AND FINDING OF MOISTURE, MINERAL RAW MATERIALS.
EA201990158A1 (en) DERIVATIVES OF BENZODIOXANE AND THEIR PHARMACEUTICAL APPLICATION
JP2009508874A5 (en)
NZ603199A (en) Orally disintegrating tablet containing acarbose
CL2007003613A1 (en) NITRO-DERIVED COMPOUNDS, ANTAGONISTS OF THE ANGIOTENSIN II RECEIVER; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT HYPERTENSION.
NO20080691L (en) Benzimidazole formulation
EA200300727A1 (en) DERIVATIVES OF 2H-1-BENZOPIRANE, METHODS OF THEIR PRODUCTION AND THEIR PHARMACEUTICAL COMPOSITIONS
FR2886846B1 (en) NOVEL USES OF GLYCEROL DERIVATIVES, IN PARTICULAR IN THE COSMETIC FIELD
MA52883A (en) PHARMACEUTICAL COMPOSITION FOR DERMATOLOGY AND ITS USES
BR112019023437A2 (en) SOLID PARTICLES
ATE418968T1 (en) RAPIDLY DISSOLVING MICROPOROUS BINDER AND PROCESS FOR PRODUCTION THEREOF

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU